Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 5/20 | 0.33 |
| ▸ | PPARD | Q03181 | 5/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5854607 | 1.00 | PTPN1 (0.36) | PTPN1HTR2BSIGMAR1TMEM97PPARG | |
| SCHEMBL5854043 | 0.99 | PTPN1 (0.37) | PTPN1HTR2BSIGMAR1TMEM97PPARG | |
| SCHEMBL5854163 | 0.96 | PTPN1 (0.37) | PTPN1HTR2BSIGMAR1TMEM97PPARG | |
| SCHEMBL5855346 | 0.91 | CYP4A11 (0.35) | PTPN1PPARGPPARDFFAR1 | |
| SCHEMBL5854269 | 0.90 | PTPN1 (0.35) | PTPN1HTR2BSIGMAR1TMEM97PPARG | |
| SCHEMBL6788841 | 0.89 | PPARG (0.34) | PTPN1HTR2BSIGMAR1TMEM97PPARG | |
| SCHEMBL5855214 | 0.89 | PTPN1 (0.35) | PTPN1HTR2BSIGMAR1TMEM97PPARG | |
| SCHEMBL5854989 | 0.89 | PPARG (0.34) | PTPN1HTR2BSIGMAR1TMEM97PPARG | |
| SCHEMBL5856744 | 0.89 | HTR2B (0.41) | HTR2BSIGMAR1TMEM97HTR1A | |
| SCHEMBL7812199 | 0.88 | PPARD (0.39) | PTPN1HTR2BSIGMAR1TMEM97PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
| EP-0944613-B1 | BENZOPYRAN DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| US-6153768-A | RECEPTOR BLOCKING ANTIESTROGENS HAVING REDUCED SIDE EFFECTS | C & C RESEARCH LABORATORIES (KR) | 2000-11-28 | — | — | US | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
| EP-0944613-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C Research Laboratories (KR) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025916-A1 | NOVEL BENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | PTPN1 384/4885HTR2B 2643/4885SIGMAR1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.